Bicara Therapeutics Inc. Accumulated Other Comprehensive Income
Bicara Therapeutics Inc. (BCAX) had Accumulated Other Comprehensive Income of -$567.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-11
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$567.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$243.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $243.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$136.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$567.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$243.00K 10-Q · filed 2026-05-11 |
| 2025-12-31 | $243.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$136.00K 10-Q · filed 2025-11-10 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |